Drug Specific Cytotoxic T-Cells in the Skin Lesions of a Patient with Toxic Epidermal Necrolysis  by Nassif, Amal et al.
COMMUNICATION
Drug Speci®c Cytotoxic T-Cells in the Skin Lesions of a
Patient with Toxic Epidermal Necrolysis
Amal Nassif, Armand Bensussan, Guillaume DorotheÂe,* Fathia Mami-Chouaib,* Nicolas Bachot,
Martine Bagot, Laurence Boumsell, and Jean-Claude Roujeau
INSERM U 448 Department of Dermatology, HoÃpital H Mondor, UniversiteÂ Paris XII, CreÂteil, France; *INSERM U487, Institut Gustave Roussy,
Villejuif, France
Toxic epidermal necrolysis is an extremely severe
drug reaction, manifesting itself by widespread apop-
tosis of keratinocytes, generally considered to result
from Fas/CD95±FasLigand interaction, but of
unknown primary mechanism. We looked at the role
of cells present in the skin blisters as probable effec-
tors of this immune reaction. In a patient suffering
from cotrimoxazole-induced toxic epidermal necro-
lysis, blister ¯uid cells were phenotyped by FACS
and tested without prior restimulation for cytotoxi-
city on autologous and allogeneic cells in the pres-
ence of the drug. Blister ¯uid lymphocytes were
predominantly CD8+, DR+, CLA+, CD56+ T lym-
phocytes, perforin positive and expressing preferen-
tially two Vb chains of the T cell receptor repertoire.
These lymphocytes were cytotoxic only in the pres-
ence of the drug towards autologous EBV trans-
formed lymphocytes and towards allogeneic cells
sharing HLA-Cw4. Cytotoxicity occurred in the
presence of either cotrimoxazole, sulfamethoxazole,
or the nitroso metabolite of sulfamethoxazole, but
not with the hydroxylamine metabolite of sulfa-
methoxazole. The lysis was blocked by an anti-MHC
class I monoclonal antibody. It was abolished by
EGTA and CMA, but neither by anti-fas, brefeldin
A, nor by anti-TRAIL receptor monoclonal anti-
bodies, strongly suggesting perforin/granzyme-
mediated cytotoxicity, without implication of Fas or
TRAIL at this stage. This is direct evidence that T
lymphocytes present within the lesions of toxic epi-
dermal necrolysis may exhibit, without any re-stimu-
lation, a drug-speci®c cytotoxicity against auto-
logous cells. Harboring the markers of classical CTL
and MHC class I restriction these lymphocytes
reacted against the parent drug and one of its react-
ive metabolites. These results challenge several cur-
rent concepts and could support new therapeutic
approaches. Key words: drug hypersensitivity/epidermal
necrolysis, toxic/major histocompatibility complex/T cell
receptor b/T lymphocytes, cytotoxic. J Invest Dermatol
118:728±733, 2002
C
linically resembling severe burns, toxic epidermal
necrolysis (TEN) is amongst the most dramatic
adverse reactions to drugs (Lyell, 1979; Roujeau
and Stern, 1994; Becker, 1998). TEN occurs in less
than 1 per 10 000 users of ``high risk'' drugs such as
anticonvulsants, antibacterial sulfonamides, oxicam-derived
NSAID, or allopurinol (Roujeau et al, 1995), but the death rate
averages 30% and many survivors suffer from sequelae, specially
affecting the eyes.
It has been proposed that the activation of the death receptor
Fas/CD95 probably plays a key role in the disseminated apoptosis
of keratinocytes that leads to epidermal necrolysis (Paul et al, 1996;
Viard et al, 1998)
The reaction most often begins 1±3 wk after the onset of a
treatment, whereas the rare recurrences begin within 2 d, suggest-
ing sensitization and speci®c immunologic memory rather than
toxicity (Roujeau and Stern, 1994). According to the current
hypothesis of the central role of reactive metabolites, reactions to
antibacterial sulfonamides are supposed to be initiated by the
compounds resulting from oxidative metabolism of the drug (Hertl
et al, 1995; Knowles et al, 2000).
In the last decade several drug-reacting T cell clones were
derived from blood mononuclear cells or from cells extracted from
the skin of a few patients with an history of drug eruption (Hertl et
al, 1995; Mauri-Hellweg et al, 1995; Schnyder et al, 1997, 2000).
The clones, obtained after re-stimulating in vitro the original cells
with the drug, had either a CD4 or a CD8 phenotype and
proliferated in the presence of the drug, its reactive metabolite, or
both (Schnyder et al, 1998; Yawalkar et al, 2000). Although
suggested by the above ®ndings, the hypothesis that TEN is
mediated by a local drug speci®c cytotoxic reaction was still lacking
de®nite proof.
The blisters created by accumulation of interstitial ¯uid under
the necrotic epidermis in patients with TEN contain rather large
amounts of T lymphocytes with a phenotype of activated cytotoxic
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cells (Correia et al, 1993; Le Cleach et al, 2000). This provided us
with an opportunity for ex vivo analysis of cells that can be regarded
as the effectors of this immune reaction.
CASE REPORT
A 50-y-old-man was treated with oral cotrimoxazole (Bactrim
forte), i.e., trimethoprim (160 mg) plus sulfamethoxazole (800 mg)
b.i.d. for infectious prostatitis, from February 25, 2000 to March
13, 2000. He received also ketoprofen and omeprazole from
February 25 to March 3. On March 10 a skin rash began that
progressed to skin detachment and oral erosions on March 14.
Detachment and blisters involved 60% of the body surface area on
March 16, erosions were present in the mouth, glans, and cornea.
Blood count was normal with the exception of a moderate
lymphopenia (800 per mL) The liver function tests were mildly
altered. High doses of intravenous human immunoglobulins were
administered over 5 d for a total dose of 2 g per kg. On March 20
the detachment had progressed to 80% of the body surface area.
There was no organ failure. Re-epithelialization began on March
23 and was nearly total on April 4 when the patient was discharged.
METHODS
An ethical committee had approved the study and the patient
provided his informed consent.
Blister ¯uid was obtained on admission by puncture of several
blisters. After centrifugation of samples, supernatant was removed
and pellets of cells were re-suspended, washed twice, and frozen in
culture medium consisting of RPMI 1640 (Gibco, Paisley, U.K.),
2 mmol L-glutamine per liter, penicillin (100 U per ml), strepto-
mycin (100 mg per ml), 20% heat inactivated human serum, and
10% DMSO. The frozen vials were stored in liquid nitrogen. Blood
lymphocytes were isolated by the technique of Ficoll-Isopaque
(Pharmacia Fine Chemicals, Piscataway, NJ) density gradient
centrifugation. The cells were washed twice and frozen in culture
medium described above. EBV-transformed B cell lines were
generated by the usual procedure (Sugden and Mark, 1977).
Anti-TCRVb and anti-CD8ab monoclonal antibodies were
purchased from Beckman-Coulter (Marseille, France), anti-Fas/
CD95 from Immunotech (Marseille, France), and anti-perforin
antibody from Bio Advance (Emerainville, France), and anti-
TRAIL R1 and R2 was kindly provided by M. Kubin at Immunex
(Seattle, U.S.A.). All other monoclonal antibodies were produced
locally.
Phenotypic analysis was performed on thawed cells, after staining
with distinct ¯uorescent monoclonal antibodies. Brie¯y, aliquots of
2 3 105 cells were incubated for 15 min at 4°C with the
corresponding antibodies. For indirect immuno¯uorescence stain-
ing, we used as second reagent an FITC-conjugated goat antimouse
immunoglobulin from Caltag Laboratories (San Francisco, CA).
Controls were done with unrelated antibodies of the same isotype.
Staining cells were analyzed using a single argon ¯ow cytometer XL
analyzer Epics (Coulter, Hialeah, FL). For the TCRVb repertoire
determination the labeling was done according to manufacturer's
recommendations (Beckman-Coulter). The distribution of Vb in
blood lymphocytes of normal controls were those provided by the
manufacturer.
Soluble Fas Ligand present in the blister ¯uid was quanti®ed by
using commercial Elisa kits from Immunotech (Marseille, France).
Cytotoxicity assays were performed according to a standard
51Cr-release method. Target cells were incubated with 100 mCi of
sodium 51 chromate (CEA, Saclay, France) for 90 min at 37°C,
washed three time in medium containing 10% human serum, and
plated at 1000 cells per well using 96 well V bottomed microtiter
plates. For blocking experiments, anti-MHC class I (W6/32), anti-
MHC class II (anti-CyE2), anti-Fas/CD 95 (ZB4), anti-TRAIL R1
and R2, irrelevant control MoAb, or EGTA were added to the
target cells for 30 min at room temperature; effector cells were
incubated for 2 h at 37°C with Brefeldin A (10 mM) or CMA
(100 nM). Assays at various effector to target (E/T) ratios were
carried out in triplicate. The ®nal culture volume was 200 ml. After
4 h of culture, plates were spun and 100 ml of supernatant was
removed from each well and counted in a gamma-counter. The
percentage of speci®c lysis was calculated with the following
formula: 100 3 [experimental release (cpm) ± spontaneous release
(cpm)]/[maximum release (cpm) ± spontaneous release (cpm)].
The percentages of speci®c chromium release by target cells
in the presence of both effector cells and the drug were calculated
as: (release with both effector cells and drug on targets) ± (release
with effector cells alone on targets)/(maximum release) ± (release
with effector cells alone on targets).
Statistical comparisons were done using paired Student t test.
Drugs used in the assays were (i) the combination of
trimethoprim and sulfamethoxazole (TMP-SMX) as marketed
(Bactrim) for intravenous injection; (ii) puri®ed sulfamethoxazole
(SMX); (iii) puri®ed hydroxylamine of sulfamethoxazole (SMX-
NOH), both kindly provided by Francoise Camus-Baud (HoÃpital
Bichat Paris, France); and (iv) puri®ed nitroso-sulfamethoxazole
(SMX-NO) kindly provided by Dean Naisbitt (Liverpool, U.K.).
Dilutions of these compounds from 10 to 100 mg per liter, i.e.,
in the range of peak serum values obtained by regular treatment
with cotrimoxazole, exhibited no signi®cant cytotoxic effect on
autologous lymphocytes. Final dilutions of 80 mg per liter SMX
were used, associated to 16 mg per liter TMP when cotrimoxazole
was tested. At these concentrations Cr release, compared with
spontaneous release, was ±1.5% 6 3.4%, ±1.6% 6 4.1%, and
±3.4% 6 3.2% for cotrimoxazole, SMX, and SMX-NOH, respect-
ively. SMX-NO has been shown to be atoxic for lymphocytes at
dilutions below 100 mM (Dean Naisbitt, Liverpool, U.K.).
RESULTS
Among blister ¯uid mononuclear cells, 65% had the size and
granularity of lymphocytes in this patient. As shown in Fig 1(a),
the predominant phenotype of these gated lymphocytes was
CD3+, CD8+ (99%) with an ab heterodimeric CD8. In addition
most cells coexpressed HLA-DR (85%), CLA (83%), and CD56
(72%) molecules. Furthermore, most cells had an ab T cell receptor
(89%). A cytoplasmic labeling by antiperforin antibody was
observed in 55% of cells (data not shown). Finally other cell
subsets were CD94+ (11%) or CD4+ (9%) (data not shown).
Upon analysis by cytometry of the TCR Vb repertoire, we
found two major Vb chains expressed ± Vb 13.1 (56%) and Vb14
(23%) ± suggesting an oligoclonal response (Fig 1b); however,
minor populations of cells expressed other Vb.
Overall the predominant lymphocyte populations in the blister
¯uid of this patient had the phenotype of activated cytotoxic
cutaneous T cells CD8+, CD3+, CD56+, CLA+.
The phenotype of blood lymphocytes differed from normal by a
moderate elevation of CLA positive cells and of Vb14 and Vb13.1
(27%, 17%, 11%, respectively, data not shown).
When tested the cells from blister ¯uid revealed no cytotoxic
effect toward autologous EBV-derived B cell line, e.g., the level of
chromium release by target cells was not signi®cantly different from
spontaneous release at all effector/target ratios.
In contrast, in the presence of cotrimoxazole, a speci®c cytotoxic
effect toward autologous B cell line was observed at all effector/
target ratios tested. The speci®c chromium release increased from
9.8% 6 5.5% to 18.3% 6 11.7% when the ratio of effector to
target cells increased from 5/1 to 40/1 (Fig 2a). For each effector/
target ratio the percentage of chromium release was signi®cantly
higher than with effector cells alone. It should be noted that no
cytotoxic activity was observed when an HLA unrelated allogeneic
B cell line was used instead of the autologous B cell line in the
presence of the drug.
This drug-dependent cytotoxicity of blister ¯uid cells was also
obtained with sulfamethoxazole and with nitroso-sulfamethoxazole,
but not with the hydroxylamine metabolite (Fig 2b), neither at the
very high concentration of 80 mg per liter nor at a more
physiologic concentration of 80 mg per liter (data not shown).
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In contrast to blister ¯uid cells, patient's puri®ed peripheral blood
lymphocytes collected during the acute phase of the disease were
not cytotoxic under the same experimental conditions (data not
shown).
Figure 1. Phenotype of lymphocytes present in the blister ¯uid of a patient with cotrimoxazole-related TEN. (a) FACS analysis of cells
present in the blister ¯uid and gated as lymphocytes. Most lymphocytes were CD3+, CD8+ (99%) and coexpressed CD56 (72%), CLA (83%), HLA-
DR (85%). Most cells had an ab T cell receptor (89%). (b) Cytometry analysis of the TCR Vb repertoire. Two major Vb chains were expressed on
the blister lymphocytes (gray bars), Vb 13.1 (56%) and Vb14 (23%), suggesting an oligoclonal response, in contrast with normal control blood
lymphocytes (black bars); however, minor populations of blister cells expressed other Vb (not shown in the ®gure).
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In order to determine whether the drug-dependent cytotoxicity
mediated by blister ¯uid cells was restricted by MHC class I
molecules, we performed MoAb blocking experiments. An anti-
class I monoclonal antibody, W6-32, abolished the drug-dependent
cytotoxic effect of blister lymphocytes toward autologous target
cells, whereas an anti-class II monoclonal antibody of the same
isotype used under the same experimental conditions had no effect
(Fig 3a).
We also determined that blister ¯uid lymphocytes were
cytotoxic in the presence of cotrimoxazole and sulfamethoxazole
toward the target lymphocytes from two allogeneic B cell lines
chosen because the ®rst one shared with the patient the two MHC
class I alleles HLA-B35 and HLA-CW4, whereas the other one
shared serologically HLA-CW4 only. In contrast no cytotoxicity
was observed when the blister ¯uid cells were tested toward
allogeneic target cells that shared HLA-A2, -B18, and -CW7 but
neither B35 nor CW4 with the patient. These results point to
HLA-CW4 as the most probable restricting element (Fig 3b).
Next we examined the molecular mechanism responsible of the
drug-dependent MHC class I restricted cytotoxicity.
To that aim, blister cells were incubated with IL-2 (100 UI per
ml) for 24 h. That induced an increase in the speci®c drug-
dependent cytotoxicity (up to 75% for a 6/1 effector/target ratio),
but no LAK cytotoxicity on target cells in the absence of drug
(Fig 4a).
Then, we used these stimulated cells to evaluate the molecular
basis of target cell killing. The drug-related cytotoxic effect was not
inhibited by a monoclonal antibody blocking the Fas receptor
(CD95) and inhibiting cell death related to Fas activation (data not
shown). The cell lysis was also unaffected by Brefeldin A, which
preferentially impairs the FasL pathway (Fig 4a). Similarly, it was
also not changed by a mixture of two monoclonal antibodies
blocking the tumor necrosis factor-related apoptosis-inducing
ligand (TRAIL) receptors (TRAIL R1 and R2). In contrast,
cytotoxicity was abolished by EGTA or by Concanamycin A
(CMA) inhibitors of perforin/granzyme-induced cell death. As the
target cells expressed CD95 and TRAIL R2 receptor (Fig 4b), our
results suggest that these receptors were not involved in the
observed drug-dependent MHC class I restricted cytotoxicity.
Figure 3. MHC class I restriction of drug-dependent cytotoxicity.
(a) Anti-class I monoclonal antibody W6-32, but not an anti-class II,
abolished drug-dependent lysis of autologous lymphocytes by blister ¯uid
cells. Grey bars, lysis of target cells without drug; black bars, lysis of target
cells in the presence of cotrimoxazole (SMX 80 mg per liter plus TMP
16 mg per liter); white bars, lysis of target cells in the presence of both
cotrimoxazole and anti-class I monoclonal antibody. Dark gray bars, lysis
of target cells in the presence of both cotrimoxazole and anti-class II
monoclonal antibody. (b) Blister ¯uid cells were tested, at an effector/
target ratio of 40/1, in the presence of cotrimoxazole on EBV-
transformed lymphocytes from two allogeneic controls sharing with the
patient a variety of serologically determined HLA class I molecules and
on a mutant cell line C1R, expressing only CW4 by serologic
determination. Lysis segregated with HLA-Cw4.
Figure 2. Drug-dependent cytotoxicity of blister ¯uid cells on
autologous lymphocytes. (a) Black bars: unstimulated blister ¯uid cells
were lytic for autologous EVB-tranformed lymphocytes preincubated
with cotrimoxazole (SMX 80 mg per liter, TMP 16 mg per liter). Blister
¯uid cells induced no cytotoxicity against autologous EVB-transformed
lymphocytes in the absence of drug (gray bars) and against unrelated
allogeneic cells preincubated with cotrimoxazole (white bars). (b)
Preincubation of target cells with sulfamethoxazole-SMX alone, 80 mg
per liter (white bar) or with the nitroso metabolite 20 mg per liter (dotted
bar) resulted in a lysis by blister ¯uid cells similar to that observed with
cotrimoxazole, i.e., SMX 80 mg per liter plus TMP 16 mg per liter (gray
bar). The hydroxylamine metabolite of sulfamethoxazole (black bar) had
no signi®cant effect as compared with the medium alone (dark gray bar)
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DISCUSSION
In a patient who developed TEN 13 d after the onset of a treatment
with cotrimoxazole, we found within the skin lesions the
accumulation of lymphocytes who had the phenotype and
functions of cytotoxic T cells. Without any further ex vivo
stimulation these cells were signi®cantly cytotoxic for autologous
lymphocytes incubated with either cotrimoxazole or sulfamethox-
azole, the sulfonamide compound of the combination drug, or its
nitroso reactive metabolite.
This is a direct demonstration that drug-speci®c MHC class I
restricted lymphocytes with cytotoxic effector functions are present
in vivo at the site where the epidermis is destroyed by massive
cytolysis. These ®ndings demonstrate the physiologic relevance of
prior studies where drug-reactive T cell clones could be derived
after long-term in vitro re-stimulation from blood or skin
lymphocytes from patients who had suffered from skin reactions
(Hertl et al, 1995; Mauri-Hellweg et al, 1995; Schnyder et al, 1997,
2000).
It is of note that a high percentage of CD8 lymphocytes present
in the blisters exhibited CD56 molecules at their cell surface. CD56
has long been considered as a marker of natural killer cells (CD56),
but recently was characterized as a good marker of highly cytotoxic
CD8 T cells (Pittet et al, 2000). We also showed that the cytotoxic
CD8 populations in this patient were restricted by the MHC class I,
a feature excluding natural killer cytotoxicity. Class I dependency
was demonstrated by the inhibition of cytotoxicity induced by an
anti-MHC class I antibody, and by the restriction of toxicity to
allogeneic target cells expressing by serologic analysis HLA-B35
and HLA-CW4 in common with the patient, and to a cell line
(C1R) expressing by serologic analysis HLA-CW4 only. Therefore
HLA-CW4 was the most probable restricting molecule; however,
as this last HLA-A, B negative mutant cell line C1R was shown to
express also low levels of HLA-B35 molecules detected by
alloreactive T cells (Zemmour et al, 1992), we cannot totally
exclude HLA-B35 as a possible restricting element.
In other studies sulfamethoxazole-reacting CD4 or CD8 clones
isolated from one patient exhibited a class I (HLA-B44) restricted
proliferation (Schnyder et al, 2000). A variety of class I phenotypes
may allow the presentation of sulfamethoxazole, probably by
allowing a noncovalent binding of the drug to class I molecules on
the cell membrane (Schnyder et al, 1997).
In this case the cytotoxic reaction depended both on
sulfamethoxazole itself and on nitroso sulfamethoxazole, one of
the reactive metabolites that had been proposed as the principal
culprit of adverse reactions to sulfamethoxazole (Knowles et al,
2000). In our experiments the cross-reactivity observed with
effector cells does not allow to determine if one of the two
compounds, or both elicited the reaction.
Drug-reacting clones previously obtained from blood lympho-
cytes of patients who had adverse reactions to cotrimoxazole mostly
reacted to sulfamethoxazole and rarely to the metabolites (Schnyder
et al, 2000).
It remains to be understood why the epidermis and a few other
epitheliums are the main targets of these severe reactions when all
other body cells express class I molecules. This could be related to
the preferential migration of lymphocytes expressing after their
activation, sugar epitopes responsible for skin-homing such as
CLA/CD162R. This is suggested by the rather high level of CLA+
lymphocytes in the blood of our patient (27%), and similar ®ndings
in other patients (Leyva et al, 2000). In addition we showed that the
CD8+ T cell population in blisters was most probably oligoclonal
and expressed Vb13.1 and Vb14. It is of note that preferential use
of Vb13.1 has been reported in skin CD8+ cells in some patients
with psoriasis (Chang et al, 1994), and use of Vb13.1 and Vb14,
both using a predominant CDR3, were studied within rheumatoid
joints (Grom et al, 1993); however, it is much too premature to
speculate on the possible role of given Vb in response to a particular
drug or on the capacity to migrate to skin.
Recent data suggested that the activation of Fas/CD95 through
Fas-L was the principal way leading to diffuse death of epidermal
cells in TEN (Viard et al, 1998). Although we detected high
concentrations of sFas-Ligand (4976 pg per liter, normal serum
concentration < 250 pg per liter) in the blister ¯uid of our patient,
we demonstrated that the strong ex vivo drug-dependent cytotoxi-
city was not mediated by interaction between CD95 and its ligand
and neither by TRAIL/TRAIL receptor pathway. That does not
preclude an involvement of Fas and/or TRAIL in vivo, specially in a
secondary nonspeci®c extension of cell death leading to the massive
lysis of epidermal cells. The ®nding of high concentrations of Fas-
ligand in the blister ¯uid is consistent with such a hypothesis.
It remains to be determined whether MHC class I restricted
CD8 cytotoxicity is the only mecanism responsible for TEN or
whether other drugs can also induce natural killer cell lysis.
Previous studies including ours reported a major CD8 T cell
population in the blister ¯uid of most patients, but often expressing
KIR/KAR molecules (Le Cleach et al, 2000). Therefore the MHC
class I restricted T cell cytotoxicity may explain only a part of TEN
cases. If further studies con®rm the role of classical drug-speci®c
Figure 4. Mediators of cytotoxicity. (a) Blister cells preincubated
with IL-2 (100 UI per ml for 24 h) exhibited an increased speci®c drug-
dependent cytotoxicity (black bar), but no LAK cytotoxicity on target
cells in the absence of drug (gray bar). This drug-dependent lysis was
totally abolished by preincubation of target cells with EGTA (dark gray
bar) but not by preincubation with monoclonal antibodies anti-CD95-Fas
(white bar) or anti-TRAIL R1 and R2 (TRAIL) (dotted bar). (b) When
effector cells were preincubated with Brefeldin A (white bar) the drug-
dependent lysis (black bar) was unaffected. In contrast it was abolished by
CMA (dark gray bar). (c) Although not implicated in the lysis, CD95-Fas
and TRAIL receptor 2 were expressed on target lymphocytes as shown
by FACS analysis.
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CD8 MHC class I restricted cytotoxicity in TEN it would provide
new therapeutic approaches.
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